Cindy Orser, PhD, Chief Science Officer ofDigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (DIGP), will present on the need for uniform cannabis testing standards at the upcoming Cannabis World Congress & Business Exposition (CWCBExpo) at the Los Angeles Convention Center. The second-annual CWCBExpo, to be held September 16–18, is the leading forum for members of the cannabis business community.

Dr. Orser will lead the panel “Setting the Standard in Cannabis Testing,” along with Dr. Andrea Small-Howard, Chief Science Officer and Director of GrowBlox Sciences, Inc., and Rob Hunt, Partner at Tuatara Capital. The presentation, which will develop the argument for standardized, uniform testing for both recreational and medical cannabis products, will take place on Thursday, September 17, in room 203A from 9:50 a.m. to 10:30 a.m.

“The CWCBExpo is the most important gathering of cannabis industry leaders. I am excited to share with them my research on the problems caused by the current patchwork system of cannabis testing, and on creating reliable, replicable standards that will ensure patient safety,” says Dr. Orser. “As our seminar will show, we can only bring legitimacy to this budding industry if we adopt testing standards that will protect patients from harmful contaminants and measure cannabinoid levels accurately for scientific study.”

As the seminar summary explains,

States that allow marijuana have been forced to individually devise their own regulations governing cannabis production, processing and quality assurance testing because marijuana is not a federally recognized useable commodity, food or drug. There is momentum advocating for cannabis industry standards. Standards not only ensure product credibility and verify new markets, they fuel development and implementation of new industries that influence the way we live and communicate; where all products are broadly tested for quality assurance; where assay protocols are validated; where the concepts behind FIFRA and the establishment of pesticide residue tolerances are determined a priori and the Food Safety and Modernization Act (FSMA) is applied; where employee and environmental protection matter; and the centralization of key testing facilities is enabled to reduce cost through the pursuit of future interstate transport.

A leader in the call for uniform standards for testing cannabis potency and safety, Dr. Orser has brought attention to the problems caused by lack of regulation and inconsistent policies at the local, state, and federal levels. Dr. Cindy Orser and CEO Todd Denkin, designed DigiPath Labs, based in Las Vegas, to be the industry leader for reliable testing. She is working closely with the State of Nevada to create the most stringent standards for cannabis testing in the nation, and she has spoken with numerous State Attorneys General about expanding these protocols to other cannabis-legal states.

Dr. Orser draws from over 25 years of experience innovating for academia and private industry. Her responsibilities have included conceptualizing and managing key projects, lab benchmarking, fundraising and budgeting, staffing, managing personnel, identifying outside collaborators and directing subcontractors. She was the liaison between her company, Big Sky Biosystems Inc., and regulatory compliance agencies such as the FDA, CDC, and ARC.

The CWCBExpo is the definitive business event for the cannabis industry, featuring the latest technologies, solutions, and resources for owners and managers of cannabis companies. This year’s keynote speakers include singer Melissa Etheridge; George Zimmer, Founder of Men’s Wearhouse; and Ethan Nadelmann, Founder and Executive Director of the Drug Policy Alliance. A number of seminars, exhibitions, and workshops will update attendees on the latest industry innovations. Registration is open at http://www.cwcbexpo.com/registration-los-angeles/.

For more information about DigiPath Labs, go to http://digipathlabs.com/.

About DigiPath, Inc. (DIGP)
DigiPath, Inc., supports the cannabis industry’s best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath’s three business units are DigiPath Labs, TNM News Corp., and DigiPath Corp.

Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements are based on information available at the time they are made, and are subject to risks and uncertainties that could cause actual performance to differ materially from those stated. For a description of the risk factors and uncertainties affecting DigiPath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.